FAAH

MK-4409 is a novel and selective inhibitor of oxazole fatty acid amide hydrolase FAAH.MK-4409 can be used to study inflammatory and neuropathic pain.

MM-433593 is a selective fatty acid amide hydrolase (FAAH-1) inhibitor for the treatment of pain, inflammation, and other disorders.

Carprofen (Ridamyl) is a propionic acid derivate and nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic activities.

N-Benzyllinolenamide is a natural product. It is an inhibitor of fatty acid amide hydrolase (FAAH, IC50 of 41.8 μM).

AM 374 (HDSF), a fatty acid amide hydrolase (FAAH) inhibitor, demonstrates the capacity to inhibit amidase activity, boasting an IC50 value of 13 nM. This compound is potentially applicable in neurological disease research.

PF 750 (ZINC27647189) is a selective and covalent inhibitor of FAAH. PF 750 shows IC50s varying from 16.2 to 595 nM in different incubation times.

Biochanin A (4-Methylgenistein) is an isoflavone derivative isolated from red clover Trifolium pratense with anticarcinogenic properties. Biochanin A is a naturally occurring fatty acid amide hydrolase (FAAH) inhibitor.

URB-597 (FAAH Inhibitor II) is an effective, orally bioavailable FAAH inhibitor (IC50: 4.6 nM), and no effect on other cannabinoid-related targets.

PF-04457845 is a greatly and effctive FAAH inhibitor, and for hFAAH(IC50=7.2±0.63 nM) and rFAAH(IC50=7.4±0.62 nM).

JZL195 is a selective and efficacious dual FAAH MAGL inhibitor.

CB2R FAAH modulator-2 (compound 26) is a dual modulator targeting CB2R and FAAH, acting as a CB2R agonist (Ki = 10.8 nM) and FAAH inhibitor (IC50 = 6.2 μM), with a Ki value of 152.9 nM for CB1R. It has research value in cancer, deleterious inflammatory cascades in neurodegenerative diseases, and COVID-19 infection.

1-Monomyristin (2,3-Dihydroxypropyl tetradecanoate) , a 1-monoglyceride of myristic acid, has antibacterial activity against several Gram-positive bacterial strains. 1-Myristoyl-rac-glycerol is used in colloidal chemistry as a nonionic surfactant in the development of micelles.

N-Benzylpalmitamide (Macamide 1) inhibits fatty acid amide hydrolase (FAAH) in a time-dependent manner and could potentially offer a good alternative for the treatment of pain, inflammation and CNS degenerative disorders.

JNJ-42165279 covalently inactivates the FAAH enzyme but is highly selective with regard to other enzymes, ion channels, transporters, and receptors. JNJ-42165279 (10 μM) exhibits high selectivity against a panel of 50 receptors, enzymes, transporters, and

PDP-EA is an activator of fatty acid amide hydrolase(FAAH) and enhances the amidohydrolase activity of FAAH.

PF-3845 is a potent, selective, and irreversible FAAH inhibitor with a Ki of 230 nM, exhibiting negligible activity against FAAH2.

VU534 is a NAPE-PLD agonist with an EC50 of 0.30 μM.VU534 is a dual inhibitor of FAAH and sEH, with an IC50 of 1.2 μM for sEH.VU534 is used in diseases related to cardiometabolism.

URB937 is an inhibitor of FAAH and increases anandamide levels(IC50 : 26.8 nM).

CB2R FAAH modulator-3 (compound 27) is a modulator targeting CB2R and FAAH, acting as a CB2R agonist with a Ki value of 20.1 nM and a CB1R agonist with a Ki value of 67.6 nM, while inhibiting FAAH with an IC50 value of 3.4 μM. This compound has research value in cancer, neurodegenerative disease-related inflammatory cascades, and COVID-19 infection.

FAAH-IN-2 (O-Desmorpholinopropyl Gefitinib) is a potent inhibitor of FAAH (fatty acid amide hydrolase).

AA38-3 (1-Piperidinecarboxylic acid, 4-nitrophenyl ester) inhibites three SHs (ABHD6, ABHD11, and FAAH)

ARN272 is a FAAH-like anandamide transporter (FLAT) inhibitor (IC50: 1.8 μM).

Dual FAAH sEH-IN-1 is a dual inhibitor of sEH (soluble epoxide hydrolase) (IC50: 9.6 nM) and FAAH (fatty acid amide hydrolase) (IC50: 7 nM) with high affinity and anti-inflammatory activity.

2-Chlorophenylboronic acid is a monohalogenated phenylboronic acid, which is an important pharmaceutical intermediate and is widely used in the synthesis of new drugs.2-Chlorophenylboronic acid has an inhibitory effect on fatty acid amidase with a Ki value of 0.01-1 µM, and is used in the study of depression, glaucoma, neuropathic pain, anxiety, migraine, I diabetes and gastritis. , migraine, type I diabetes and gastritis.

FAAH inhibitor 1 (Benzothiazole analog 3) is a potent FAAH inhibitor with an IC50 of 18 nM.

WWL 154 is an serine hydrolase (SH) and fatty acid amide hydrolase FAAH-4 inhibitor.

N-(3-Methoxybenzyl)Palmitamide is a promising FAAH inhibitor for the treatment of pain, inflammation, and CNS degenerative disorders.

CB2R FAAH modulator-1, a cannabinoid type 2 receptor (CB2R) agonist, is also a fatty acid amide hydrolase (FAAH) inhibitor (IC50=4 μM) that reduces the production of pro-inflammatory and anti-inflammatory cytokines and is commonly used in inflammation studies. The Kis for CB2R and CB1R are 14.8 nM and 241.3 nM, respectively.

LY2183240 inhibits fatty acid amide hydrolase (FAAH) activity (IC50 = 12.4 nM). LY2183240 is a novel and highly effective blocker of anandamide uptake (IC50 = 270 pM).

JNJ-1661010 (Takeda-25) is an effective and specific FAAH inhibitor (IC50: 10 12 nM for rat human), shows >100-fold selectivity for FAAH-1 than FAAH-2.

4-Nonylphenylboronic acid is a inhibitor of FAAH.

BIA 10-2474 is a long-acting reversible inhibitor of fatty acid amide hydrolase (FAAH) that increases levels of the neurotransmitter anandamide in the central nervous system and in peripheral tissues (that is, the rest of the body other than the brain and spinal cord). BIA 10-2474(BIA10-2474) interacts with the human endocannabinoid system. BIA 10-2474(BIA10-2474) was in development for the treatment of a range of different medical conditions from anxiety to Parkinson's disease, also for the treatment of chronic pain of multiple sclerosis, Y, hypertension or the treatment of obesity.

Palmitoylisopropylamide is a selective FAAH inhibitor that inhibits [H]-AEA uptake and cell proliferation at low concentrations.

JNJ-40355003 is a specific fatty acid amide hydrolase (FAAH) inhibitor that increases plasma levels of fatty acid amides in rats, dogs, and crabs.

FAAH-IN-1 is a fatty acid amide hydrolase (FAAH) inhibitor with IC50 values of 145 nM for rat FAAH and 650 nM for human FAAH.

MK-3168 (12C) functions as a FAAH inhibitor, exhibiting IC50 values of 1.0 nM, 5.5 nM, and 1.7 nM for human, rhesus, and rat respectively. It demonstrates effective brain uptake and FAAH-specific signaling. Additionally, 11 C MK-3168 is applicable as a FAAH PET tracer.

SA57 is a potent, selective inhibitor of FAAH(IC50s of 3.2 nM and 1.9 nM for mouse and human FAAH).

Isopropyl dodec-11-enylfluorophosphonate (IDEFP) is an organophosphorus ester that serves as a central cannabinoid receptor (CB1) antagonist and equally inhibits fatty acid amide hydrolase (FAAH), both with an IC50 value of 2 nM [1].

JP104 is an aryl carbamate that irreversibly inhibits fatty acid amide hydrolase (FAAH) with a pIC50 value of approximately 8 [1].

BuChE-IN-15, a chemical compound, exhibits potent inhibitory activity with IC50 values of 81 nM and 400 nM, respectively. It also demonstrates good blood-brain barrier permeability and neuroprotective properties, making it suitable for research in Alzheimer's disease.

Sob-AM2 is an effective substrate targeting the fatty acid amide hydrolase (FAAH) expressed in the brain, with a Km of 1.3 μM. It delivers higher concentrations of Sobetirome to the central nervous system at minimal peripheral systemic doses, thereby activating the central thyroid hormone receptor β (TRβ).

SA 47 is a selective and effective inhibitor of fatty acid amide hydrolase (FAAH) and carbamate.